Novo Nordisk today announced headline results from a phase 2a clinical trial with monlunabant, a small molecule oral ...

Novo Nordisk Inc. was sued Friday by five former employees who say the pharmaceutical company mismanages its $2.3 billion ...

Bagsværd, Denmark, 16 September 2024 – On 7 August 2024, Novo Nordisk initiated a share repurchase programme in accordance with Article 5 of Regulation No 596/2014 of the European Parliament ...

The Federal Trade Commission (FTC) has filed a legal complaint accusing the 3 largest pharmacy benefit managers (PBMs) in the ...

Health-care companies fell amid fears of pharmaceutical drug-price controls. Novo Nordisk's Ozempic is "very likely" to be one the next drugs to have its price slashed in bargaining with the U.S.

Novo Nordisk is paying $55 million upfront to secure rights to a cell therapy for heart failure developed by Japanese startup Heartseed. The Danish drugmaker has acquired exclusive rights outside ...

The company noted that Wegovy is the first obesity medication to receive a positive opinion recommending a label update that reflects reduced symptoms and improved physical limitations and exercise ...

Diabetes medication shortages are nothing new. The most recent example concerns NovoNordisk’s drug Ozempic, originally designed to help the pancreas make more insulin but gained meteoric popularity ...

DOWN BALLOT — The Forward Majority super PAC has surged its planned spending to $45 million to elect Democrats to statehouses ...

The pair boast the two biggest candidates in the market, with NovoNordisk’s Wegovy/Ozempic (semaglutide) expected to make ...

The browser you are using is no longer supported on this site. It is highly recommended that you use the latest versions of a supported browser in order to receive an optimal viewing experience.

Novo Nordisk expects to repurchase B shares for an amount up to DKK 20 billion during a 12-month period beginning 6 February 2024. As of 13 September 2024, Novo Nordisk has since 6 February 2024 ...